Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 27 Sep 2026 · Editorial standards

At a glance

ModernaTX is the lead sponsor of 28 current clinical trials in our USA, UK, Canada, Australia, Spain, France, Netherlands, Japan, Mexico, Italy, Poland, Germany and South Korea registers. 12 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are Pembrolizumab, MRNA-1189 and Efluelda (TIV-HD) and Spikevax. The most-studied condition is SARS-CoV-2.

ClinicalTrials.gov trials by status

Recruiting1243%
Not yet open14%
Active, closed1554%

Trials by phase

Phase 1/2829%
Phase 1829%
Phase 2518%
Observational311%
Phase 327%
Phase 427%

Clinical trials sponsored by ModernaTX

28 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705 NCT05295433 · Methylmalonic Acidemia	Phase 1/2	Recruiting	2022-03	UK, USA, France, Spain, Netherlands, Canada
A Retrospective Study to Characterize Participants With Propionic Acidemia NCT05769621 · ClinicalTrials.gov ↗ · Propionic Acidemia	Observational	Recruiting	2023-06	UK, USA, France, Spain, Italy, Netherlands, Canada, Japan, Australia
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors NCT05533697 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drugs: Ipilimumab, Nivolumab, Pembrolizumab	Phase 1/2	Recruiting	2022-09	UK, USA, Germany, Spain, Italy, Poland, Australia
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors NCT06880549 · Advanced Solid Tumors Drug: Pembrolizumab	Phase 1	Recruiting	2025-03	USA
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years NCT06735248 · ClinicalTrials.gov ↗ · Multiple Sclerosis Drug: MRNA-1195	Phase 2	Recruiting	2025-04	UK, USA, Australia
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults NCT07764237 · ClinicalTrials.gov ↗ · Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (hMPV) Drugs: MRNA-1345, MRNA-1365	Phase 1	Recruiting	2026-08	UK, Canada
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia NCT04159103 · ClinicalTrials.gov ↗ · Propionic Acidemia Drug: MRNA-3927	Phase 1/2	Recruiting	2021-04	UK, USA, France, Spain, Netherlands, Canada, Japan
A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants NCT06655870 · ClinicalTrials.gov ↗ · Healthy Participants	Phase 1	Recruiting	2024-10	Australia
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age NCT07478952 · ClinicalTrials.gov ↗ · Epstein-Barr Virus Drug: MRNA-1189	Phase 1	Recruiting	2026-03	Australia
A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study NCT05130437 · ClinicalTrials.gov ↗ · Propionic Acidemia Drug: MRNA-3927	Phase 1/2	Recruiting	2021-11	UK, USA, France, Spain, Netherlands, Canada, Japan
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma NCT07116616 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma	Phase 1/2	Recruiting	2025-09	USA
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations NCT06585241 · ClinicalTrials.gov ↗ · SARS-CoV-2	Phase 4	Recruiting	2024-09	USA
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age NCT07808697 · ClinicalTrials.gov ↗ · SARS-CoV-2 Drugs: Efluelda (TIV-HD) and Spikevax, MRNA-1283	Phase 2	Not yet open	2026-09	USA, Mexico
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age) NCT07561294 · ClinicalTrials.gov ↗ · Lyme Disease	Phase 2	Active, closed	2026-04	Canada
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age NCT05992935 · Norovirus Acute Gastroenteritis Drug: MRNA-1403	Phase 1/2	Active, closed	2023-08	USA, Australia
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months NCT05743881 · ClinicalTrials.gov ↗ · Respiratory Syncytial Virus, Human Metapneumovirus Drugs: MRNA-1345, MRNA-1365	Phase 1	Active, closed	2023-02	UK, USA, Mexico
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis NCT06592794 · ClinicalTrials.gov ↗ · Acute Gastroenteritis, Norovirus Acute Gastroenteritis Drug: MRNA-1403	Phase 3	Active, closed	2024-09	UK, USA, Canada, Mexico, Japan, Australia
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) NCT07266558 · SARS-CoV-2 Drugs: Efluelda (TIV-HD) and Spikevax, MRNA-1283	Phase 4	Active, closed	2025-11	USA
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) NCT05095727 · ClinicalTrials.gov ↗ · Glycogen Storage Disease	Phase 1/2	Active, closed	2022-06	USA, France, Spain, Netherlands, Poland, Canada
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) NCT03897881 · ClinicalTrials.gov ↗ · Melanoma Drugs: Intismeran autogene, Pembrolizumab	Phase 2	Active, closed	2019-07	USA, Australia
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors NCT03313778 · ClinicalTrials.gov ↗ · Solid Tumors Drugs: Intismeran autogene, Pembrolizumab	Phase 1	Active, closed	2017-08	UK, USA, Japan, Australia
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults NCT07496450 · ClinicalTrials.gov ↗ · Influenza	Phase 3	Active, closed	2026-03	UK, USA
Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE NCT06333704 · ClinicalTrials.gov ↗ · SARS-CoV-2 Drug: Spikevax	Observational	Active, closed	2023-03	South Korea
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants NCT05831111 · ClinicalTrials.gov ↗ · Epstein-Barr Virus Infection Drugs: MRNA-1189, MRNA-1195	Phase 1	Active, closed	2023-04	USA
A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants NCT07737717 · ClinicalTrials.gov ↗ · Ebola-Bundibugyo Virus Disease (Ebola-BDBV)	Phase 1	Active, closed	2026-07	Canada
A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX) NCT06189053 · ClinicalTrials.gov ↗ · Myocarditis	Observational	Active, closed	2022-04	USA
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults NCT05164094 · ClinicalTrials.gov ↗ · Epstein-Barr Virus Infection Drug: MRNA-1189	Phase 1/2	Active, closed	2021-12	USA
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. NCT05683457 · ClinicalTrials.gov ↗ · Cytomegalovirus Infection	Phase 2	Active, closed	2023-04	USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in ModernaTX trials

13 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Pembrolizumab4 MRNA-11893 Efluelda (TIV-HD) and Spikevax2 Intismeran autogene2 MRNA-11952 MRNA-12832 MRNA-13452 MRNA-13652 MRNA-14032 MRNA-39272 Ipilimumab1 Nivolumab1 Spikevax1

Conditions in ModernaTX trials

23 conditions

SARS-CoV-24Propionic Acidemia3Advanced Solid Tumors2Norovirus Acute Gastroenteritis2Epstein-Barr Virus Infection2Methylmalonic Acidemia1Respiratory Syncytial Virus1Human Metapneumovirus1Multiple Sclerosis1Respiratory Syncytial Virus (RSV)1Human Metapneuomovirus (hMPV)1Acute Gastroenteritis1Influenza1 Solid Tumors1 Melanoma1Glycogen Storage Disease1Relapsed or Refractory Multiple Myeloma1Myocarditis1Cytomegalovirus Infection1Lyme Disease1Ebola-Bundibugyo Virus Disease (Ebola-BDBV)1Healthy Participants1Epstein-Barr Virus1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	22	9
Clinical trials in UK	11	7
Clinical trials in Canada	9	5
Clinical trials in Australia	9	5
Clinical trials in Spain	6	5
Clinical trials in France	5	4
Clinical trials in Netherlands	5	4
Clinical trials in Japan	5	3
Clinical trials in Mexico	3	0
Clinical trials in Italy	2	2
Clinical trials in Poland	2	1
Clinical trials in Germany	1	1
Clinical trials in South Korea	1	0

A trial with sites in more than one country appears in each of those registers.

Other sponsors in SARS-CoV-2

Sponsor	Trials
Shionogi	1

Sponsors with the most current trials registered for this condition.

Questions about ModernaTX trials

How many clinical trials does ModernaTX sponsor?

ModernaTX is the lead sponsor of 28 current trials on ClinicalTrials.gov in our USA, UK, Canada, Australia, Spain, France, Netherlands, Japan, Mexico, Italy, Poland, Germany and South Korea registers, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are ModernaTX trials recruiting?

Yes. 12 of its 28 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is ModernaTX testing?

Its current trials name 13 drugs and biologicals as interventions. The most frequent are Pembrolizumab (4), MRNA-1189 (3), Efluelda (TIV-HD) and Spikevax (2), Intismeran autogene (2) and MRNA-1195 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

ModernaTX clinical trials